Troy Guthrie, MD
Medical Oncology · Jacksonville, FLNPI 1073500328
Payments from drug & device makers
Across 205 payments — averaging $5423.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Beigene, Ltd.$496K
- Seagen Inc.$335K
- E.r. Squibb & Sons, L.L.C.$74K
- United Therapeutics Corporation$63K
- Janssen Research & Development, LLC$33K
- Sanofi US Services Inc.$23K
- plus $87K from 33 others
What the payments were for
- Food & beverage$1,24099%
- Education$181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Beigene, Ltd. | 26 | $496,174 |
| Seagen Inc. | 24 | $334,989 |
| E.r. Squibb & Sons, L.L.C. | 16 | $73,902 |
| United Therapeutics Corporation | 9 | $63,481 |
| Janssen Research & Development, LLC | 4 | $32,752 |
| Sanofi US Services Inc. | 22 | $23,050 |
| Helsinn Healthcare SA | 5 | $16,438 |
| Pfizer | 10 | $16,405 |
| Halozyme Inc | 1 | $15,600 |
| Incyte Corporation | 18 | $14,400 |
| Chiesi USA, Inc. | 1 | $8,000 |
| Amgen | 10 | $5,702 |
| Mirati Therapeutics, Inc. | 1 | $2,883 |
| Novocure Inc. | 1 | $2,600 |
| Astellas Pharma Global Development | 8 | $2,064 |
| Pharmacyclics LLC, An Abbvie Company | 7 | $1,215 |
| Taiho Oncology, Inc. | 1 | $900 |
| Argenx US, Inc. | 1 | $500 |
| GSK | 1 | $113 |
| Bio Products Laboratory USA, Inc. | 8 | $90 |
| Johnson & Johnson | 4 | $80 |
| Novartis | 5 | $70 |
| Apellis Pharmaceuticals, Inc. | 2 | $55 |
| Merck | 2 | $39 |
| Bayer | 2 | $35 |
| EMD Serono, Inc. | 2 | $32 |
| Exelixis Inc. | 2 | $30 |
| Astellas Pharma US Inc | 1 | $26 |
| Eisai Inc. | 1 | $24 |
| Genentech USA, Inc. | 1 | $22 |
| AbbVie | 1 | $22 |
| Servier Pharmaceuticals LLC | 1 | $20 |
| Rigel Pharmaceuticals, Inc. | 1 | $19 |
| AstraZeneca | 1 | $18 |
| Sanofi | 1 | $18 |
| Scpharmaceuticals Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $13 |
| Verastem, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,111,820 in reported general payments places this provider in the 80th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 33 | $748,725 |
| BrukinsaZanubrutinib | 30 | $451,430 |
| ImbruvicaIbrutinib | 21 | $390,394 |
| TibsovoIvosidenib | 11 | $362,166 |
| XtandiEnzalutamide | 20 | $290,615 |
| RevlimidLenalidomide | 22 | $252,095 |
| JakafiRuxolitinib Phosphate | 12 | $208,417 |
| IbrancePalbociclib | 14 | $206,658 |
| OxbrytaVoxelotor | 15 | $186,269 |
| Abiraterone Acetate | 80 | $151,223 |
| EliquisApixaban | 127 | $95,844 |
| Fondaparinux Sodium | 18 | $22,245 |
| XareltoRivaroxaban | 21 | $15,351 |
| Exemestane | 32 | $8,798 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 144 | $6,277 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $73,902 | $748,72533 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $1,215 | $390,39421 claims |
| Servier Pharmaceuticals LLCTibsovo | $20 | $362,16611 claims |
| PfizerIbrance, Eliquis | $16,405 | $302,502141 claims |
| Astellas Pharma US IncXtandi | $26 | $290,61520 claims |
| Incyte CorporationJakafi | $14,400 | $208,41712 claims |
| Johnson & JohnsonXarelto | $80 | $15,35121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 507 medical oncology providers in Florida.
Other medical oncology in Jacksonville
- Zeynep ErogluTampa$30.9M
- Manish PatelSarasota$29.7M
- Jad ChahoudTampa$21.8M
- Maen HusseinTavares$18.4M
- Patrick HwuTampa$18M
- Gail WrightHudson$13.8M
- Adil DaudTampa$13.3M
- Lowell HartFort Myers$10.1M
- Judy WangSarasota$9.8M
- Jonathan StrosbergTampa$9.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.